Oncolytics Biotech Inc T.ONC

PFIZER no stone unturned in looking for new deals

[askretka]

On heels of record-breaking Q2, Pfizer CEO Albert Bourla outlines plans to go very big on BD Nicole DeFeudis Editor Pfizer CEO Albert Bourla uncorked some record-breaking Q2 numbers on Thursday, including the companys highest-ever quarterly sales thanks to Comirnaty and Paxlovid, all while raising the full-year guidance. Whats he going to do with that cash? ----------- Go very big on new deals, he said on the companys Q2 call with investors. --------- Were leaving very few stones unturned when we look at opportunities, chief business innovation officer Aamir Malik added. Were going to be very open to deal structures, and weve said before were also going to be agnostic to size. ---------- Execs hope the BD strategy will add $25 billion in risk-adjusted revenue by 2030 and theyre well on their way, according to Malik. The recent Biohaven takeover alone is expected to add $6 billion in peak sales revenue, he said. --------------- Cheers!!!!!

[Noteable]

In line with Pfizer's pronouncement of 'going big' on its business development (M&A) activities, which had been speculated here beforehand, Pfizer stated that it "is certain that its CD47 portfolio won't get gobbled up by the kind of clinical woes that have befallen its rival Gilead" as stated in yesterday's Q&A session following Pfizer's Q2 earnings

[Noteable]

Comments made by Pfizer's Amir Malik during Q2 earnings CC  "Let me just start with your specific FTC point. I think we've demonstrated a very strong track record of shepherding our transactions to-date through the regulatory process. And that's been largely built on having just a close successful, constructive, and collaborative relationships with regulatory bodies globally

[Noteable]

Pfizer is on the hunt for deals per Aamir Malik at Pfizer's Q2 2022 CC ... "So most of the deals that we do are pro-patient and they're pro-innovation. So we're confident that we can continue to advance our BD strategies in a successful way." This strongly suggests that Pfizer (and others big pharma companies as we are recently witnessing) is ready to make a plethora of